Details for Patent: 9,132,239
✉ Email this page to a colleague
Which drugs does patent 9,132,239 protect, and when does it expire?
Patent 9,132,239 protects OZEMPIC and SAXENDA and is included in two NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirteen patent family members in eleven countries.
Summary for Patent: 9,132,239
| Title: | Dial-down mechanism for wind-up pen |
| Abstract: | The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm (21) engaging a ring element (10) and a reset element (30) which acts on a knob located on the periphery of the ratchet arm (21) to move the ratchet arm (21) out of engagement with the ring element (10) in order to allow the set dose to be reduced. |
| Inventor(s): | Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK), Radmer; Bo (Hillerod, DK), Enggaard; Christian Peter (Vejby, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 13/124,995 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,132,239 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 9,132,239
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,132,239
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 08167547 | Oct 24, 2008 | |
| PCT Information | |||
| PCT Filed | October 21, 2009 | PCT Application Number: | PCT/EP2009/063801 |
| PCT Publication Date: | April 29, 2010 | PCT Publication Number: | WO2010/046394 |
International Family Members for US Patent 9,132,239
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009306387 | ⤷ Try a Trial | |||
| Brazil | PI0919925 | ⤷ Try a Trial | |||
| Canada | 2738877 | ⤷ Try a Trial | |||
| China | 102196835 | ⤷ Try a Trial | |||
| Denmark | 2373361 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
